FGF21, fibroblastic growth factor 21, a hormone produced from the liver, adipose tissue, pancreas and muscles, has in recent years emerged as a major regulator of glucose, lipid and energy metabolism. It exerts pleiotropic beneficial effects in multiple target organs, mediated through endocrine, paracrine and autocrine actions. Paradoxically, circulating levels are found to be raised in obesity and type 2 diabetes, suggesting the presence of FGF21 resistance or a compensatory response to the underlying metabolic disturbance or tissue injury. Indeed, FGF21 resistance has been demonstrated in the adipose tissue of both humans and mice, consequent to the enhanced expression of pro-inflammatory cytokines and microRNA-34a. In the pancreatic islet, hyperglycemia also impairs the action of FGF21, through repression of the co-receptor protein b-Klotho, probably via reduced PPARc expression. Epidemiologically, a raised serum FGF21 level has been shown to be as good as the oral glucose tolerance test in predicting incident type 2 diabetes. In contrast, serum FGF21 levels are reduced in autoimmune diabetes, including LADA and type 1 diabetes, with the levels correlating positively with C-peptide levels and inversely with titres of autoimmune antibodies related to b-cell destruction. The role of FGF21 in the bodily response to tissue injury has been demonstrated in the liver and the pancreas, in part through the enhancement of anti-oxidant capacity. Studies in FGF21 knockout mice suggest that FGF21 plays a physiological role in protecting against islet inflammation, hyperplasia and dysfunction, in the context of obesity and diabetes. On the other hand, rat islets treated with FGF21 are partially protected from glucolipotoxicity and cytokine-induced apoptosis, and FGF21 treatment prevents islet destruction and onset of hyperglycemia in New Zealand obese mice. Furthermore, administration of FGF21 analogs of sustained action to db/db mice has been shown to enhance pancreatic insulin content, islet number and glucose-dependent insulin secretion, while reducing plasma glucagon levels. FGF21 may also reduce lipotoxicity to the b-cells through its beneficial effects on lipid metabolism, including the suppression of lipolysis and hepatic sterol regulatory element-binding protein-2, and the enhanced expression of adiponectin. The physiological relevance of circulating FGF21 in humans is supported by its genetic regulation, its responses to meal-related fatty acid changes and treatment with PPAR-a/PPAR-c agonists. The therapeutic potential of FGF21-targeting approaches in the treatment of diabetes and other obesity-related cardiometabolic disorders, using FGF21 mimetics or enhancers, is under active research in animal and human studies.
Diabetes mellitus is a complex disease characterized by hyperglycemia resulting from defective insulin secretion and action. Familial aggregation, ethnic heterogeneity and twin studies have indicated that genetic factors are of pivotal importance in the onset of diabetes. With the evolution of genetic techniques, familybase linkage analysis, candidate-gene approaches and genome-wide association studies (GWAS) have been widely used to elucidate the genetic characteristics of diabetes in Chinese population.
As a form of polygenetic diabetes, over 100 genes were identified to be susceptible genes of type 2 diabetes. Most of them were linked to beta-cell function. Moreover, we constructed the genetic risk score (GRS) with multiple loci to test the effect of genetics in the 9-year follow-up perspective cohort. The weighted GRS can predict blood glucose deterioration through its effect on beta-cell function in the Chinese population. Individuals in the intermediate-or high-weighted GRS group exhibited progressive deterioration of beta-cell function. Therefore, this GRS model can be used to predict the high-risk population of diabetes in the 9-year follow-up perspective cohort.
For monogenetic diabetes, we have explored more than 80 novel causative mutations responsible for special types of diabetes like maturity onset diabetes of the young (MODY), Wolfram syndromes and neonatal diabetes mellitus through whole-exome sequencing. We identified a causative mutation in INS p.Ala2Thr responsible for MODY10 in a Chinese population. We demonstrated that this mutation can activate the PERK-eIF2a-ATF4, IRE1a-XBP1, and ATF6 pathways as well as upregulate ER chaperones. Therefore, this novel mutation INS p.Ala2Thr affected b cell function by inducing ER stress.
In summary, genetic data in Chinese population demonstrated that the main cause of diabetes in China is impaired beta-cell function.
S-1-2
The genetic and clinical determinants of insulin secretagogue efficacy and the potential mechanisms Q. Ren Department of Endocrinology and Metabolism, Peking University People's Hospital Sulfonylureas are among the most widely used oral hypoglycaemic agents in the treatment of type 2 diabetes. However, there is also considerable inter-individual variation in the response to sulfonylureas, and the mechanisms underlying these different responses to sulfonylureas are still not fully understood. In this presentation, we reviewed the clinical biomarkers and genetic background influencing the antidiabetic efficacy of sulfonylurea in type 2 diabetic patients. And we investigated the clinical and genetic biomarkers in patients with type 2 diabetes. All the participants in our study were enrolled from a clinical trial that had a prospective design and strict drug dose adjustment and data collection. We also assessed the potential utility of combining information from multiple genetic determinants and clinical biomarkers to predict sulfonylurea response. Our study may give evidence for personalized medicine in type 2 diabetes in the future.
S-1-3
Insulin secretion function index as an independent predictor of major adverse cardiovascular events in a long-term population-based Chinese cohort Insulin resistance has an important pathogenic role not only in diabetes, but also in cardiovascular diseases. Several large population-based studies have shown that hyperinsulinemia, a surrogate marker for insulin resistance, predicts incident coronary artery disease. It has been demonstrated that about 25% of an apparently healthy population is insulin resistant enough to have significantly increased risk of coronary heart disease. The homeostasis model assessment (HOMA), based on plasma levels of fasting glucose and insulin, has been widely validated and applied for quantifying insulin resistance (HOMA-IR) as well as b-cell function (HOMA-beta). While both models have been shown to associate with diabetes development, the association between increased cardiovascular risk was mainly found in HOMA-IR but not in HOMA-beta models. Impaired beta-cell function plays an important role in the pathogenesis of diabetes in Asians. Studies have shown that reduced first-phase insulin secretion was observed in overweight subjects who are normoglycaemic. The failure to compensate for insulin resistance suggests that insulin secretion dysfunction may be the predominant culprit in the pathogenesis of type 2 diabetes. We are therefore interested to examine the association of HOMA-beta, a measurement of beta-cell function, with incident major adverse cardiovascular events (MACE), which included acute myocardial infarction, acute coronary syndrome, stroke, peripheral vascular disease, and cardiovascular death in the participants of the prospective communitybased Hong Kong Cardiovascular Risk Factors Prevalence Study (CRISPS). Cox proportional hazards regression was performed to evaluate the associations of clinical parameters, obesity indices, medical history and insulin indices with MACE. In a 22-year follow-up of 2594 participants, with 281 MACE events, we found that low HOMA-beta, instead of HOMA-IR, significantly predicted incident MACE in the multivariable Cox regression model. Whether or not beta-cell dysfunction, as measured by HOMA-beta, is a better indicator to predict future cardiac events in the Asian warrants further investigation.
S-1-4 3-D human islet histology in health and disease
S.-C. Tang National Tsing Hua University, Taiwan Scattered in the pancreatic parenchyma, the endocrine islets rely on neurovascular networks for signal relay to regulate and synchronize hormone secretion. However, due to the dispersed nature of the network architecture, standard microtome-based histology cannot provide a globe view of the islet tissue networks in health and disease. In this talk, I will discuss the approach of using 3-D histology with tissue clearing to examine the human islet microstructure, vasculature, and innervation in an integrated fashion. Examples will be given on how to visualize the remodeling of pancreatic and islet microenvironment in fatty infiltration, early duct lesion formation, and neuroendocrine tumor. The long-term goal of our work was to establish "3-D histology" as a preferred method for the pancreatic and islet tissue analyses.
S-1-5
Simplified pancreatic tissue clearing technology and three-dimensional (3D) confocal microscopy imaging to understand the role of Exchange Protein Activated by cAMP in pancreatic beta cells and islets
S. K. Chung
The University of Hong Kong, Hong Kong BACKGROUND: cAMP is a second messenger that is involved in many biological processes. In 1998, a new target of cAMP called Exchange Protein Activated by cAMP (Epac) was discovered and thought to be responsible for cellular signals independent of the cAMP-protein kinase A (PKA) and cyclic nucleotide-gated ion channel signaling pathway. Previously, Epac1 homozygous knockout (Epac1-/-) mice were generated and found to develop metabolic syndromes with impaired glucose-stimulated insulin secretion (GSIS) and defect in pancreatic beta-cell proliferation and differentiation from ES cells with Epac1 deletion. Here, we hypothesize that Epac1 plays an important role in beta cells of pancreatic islet and justify the detailed in vivo three-dimensional (3D) imaging analysis and quantification of entire pancreatic islets and beta cells from wild-type (Epac1 + /+) and Epac1 knockout (Epac1-/-) mice to determine the effect of Epac1 deficiency and metabolic syndrome on the cytoarchitecture of pancreatic islets. MATERIAL AND METHODS: The simplified faster tissue clearing technique (CLARITY) protocol was developed to minimize the pre-existing optical barriers, light scattering and light absorption in order to achieve a high-resolution 3D imaging of the entire pancreas by confocal microscopy. To determine pancreatic tissue and islet integrity, we used 6-week-old transgenic mice with overexpression of green fluorescent protein (GFP) under the mouse insulin I promoter (MIP). These MIP-GFP transgenic mice allowed a visualization of GFP-labeled pancreatic insulin-secreting beta cells and islets in three-dimensional (3D) imaging using the confocal microscope. To further determine the role of Epac1 in pancreatic islets and beta cells in entire pancreas, wild-type (Epac1 + /+) and Epac1-/-mice were crossed with MIP-GFP mice. RESULTS: The simplified CLARITY protocol for the smaller pancreas from 6-week-old mice was able to render the pancreas transparent, preserve endogenous fluorescence and allowed high-resolution 3D confocal microscopy imaging. Analysis revealed that 6-week-old Epac1-/-mice have significantly higher beta-cell number or mass than age-matched Epac1 + /+ mice. CONCLUSION: The new, simple and direct CLARITY method and 3D imaging of pancreas from MIP-GFP mice with or without Epac1 are useful tool to study the effect of metabolic syndrome on the cytoarchitecture of entire pancreatic islets and beta cells. The present study complements our previously reported study on the quantitation of pancreatic islets of Epac1 + /+ and Epac1-/-mice using a conventional histological methodology.
S-2-2
The mechanism of incretin responsiveness in pancreatic beta cells The incretins, GLP-1 and GIP, which are secreted from enteroendocrine cells in response to meal ingestion, play critical roles in preventing postprandial hyperglycemia by potentiating insulin secretion from pancreatic b cells. By a metabolomics-based approach using incretin-responsive and -unresponsive MIN6 b-cell lines, designated MIN6-K8 and -K20, respectively, we previously found that glutamate produced by glucose stimulation acts as a key signaling molecule in incretininduced insulin secretion (IIIS) (Gheni et al., Cell Rep, 2014). Cytosolic glutamate is produced through the malate-aspartate (MA) shuttle linked to glycolysis and is transported into insulin granules through vesicular glutamate transporters (VGLUTs) via incretin/cAMP signaling, resulting in potentiation of insulin secretion. To confirm this finding, we recently established MIN6-K8 b-cell lines deficient for aspartate aminotransferase 1 (AST1), an enzyme in the MA shuttle, and for VGLUT1, 2, and 3 by CRISPR/Cas9 system (Murao et al., PLoS One, 2017). AST1 knockout (KO) cells or VGLUT1, 2, and 3 triple KO cells showed impaired IIIS, providing direct evidence that b-cell glutamate signaling is essential in IIIS.
In the course of our study of the MIN6-K20 b-cell line which is incretin unresponsive under monolayer culture (called K20-MC), we found that formation of spheroid clusters (called K20-SC) drastically induced incretin responsiveness (Iwasaki et al., J Diabetes Investig, 2010). We recently tried to elucidate the mechanism by which incretin responsiveness is acquired using K20-SC as a model (Hashim et al., Diabetes, in press). Expression of the amino acid transporter SNAT5 was downregulated in K20-SC and pancreatic islets of normal mice, whereas it was upregulated in K20-MC and islets of mouse models of obesity and diabetes. Inhibition of SNAT5 significantly increased cellular glutamate content and improved IIIS both in K20-MC and in islets of these models. These findings suggest that suppression of SNAT5 activity confers incretin responsiveness on incretin-unresponsive b cells. Elucidation of the mechanism of SNAT5 regulation may lead to better treatment of diabetes as well as further understanding of incretin unresponsiveness in diabetes and obesity.
S-2-3
GLP-1 secretion and vagal afferent mediate anti-diabetes/obesity effects of rare sugar D-allulose dyslipidemia, glucose intolerance and insulin resistance. These acute and subchronic effects are blunted by vagotomy or pharmacological GLP-1R blockade, and by genetic inactivation of GLP-1R signaling in whole body or selectively in vagal afferents. These results demonstrate that D-allulose serves as a prominent GLP-1 releaser, providing a novel category of incretin-related substance/drug. Furthermore, it acts through a selective pathway of vagal afferents to inform the brain, thereby restricting feeding and hyperglycemia. Subchronic D-allulose, when administered time specifically at LP but not dark period, corrects arrhythmic overeating, obesity and diabetes. Hence, chronotherapeutic modulation of GLP-1R signaling in vagal afferents may help treat arrhythmic overeating, obesity and diabetes.
S-2-4
Mechanisms of gastric inhibitory polypeptide (GIP) secretion from K cells in response to nutrients N. Harada, S. Yamane and N. Inagaki Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Gastric inhibitory polypeptide (GIP) is an incretin secreted from enteroendocrine K cells in response to glucose and fat ingestion. GIP potentiates insulin secretion through the GIP receptor (GIPR) expressed in pancreatic b cells. GIP plays an important role in maintaining blood glucose levels by inducing hypersecretion of insulin in high-fat diet (HFD)-induced obesity. GIPR expressed in adipose tissue is involved in HFD-induced insulin resistance. Thus, GIP is a key hormone for fat accumulation. Gene expression in K cells and mechanisms of GIP secretion remain unclear, because it is difficult to isolate K cells from intestinal mucosal epithelial cells and there is no ideal cell line to evaluate GIP secretion. We generated GIP reporter mice which enable us to visualize and isolate K cells by enhanced green fluorescent protein (EGFP).
Fat ingestion strongly stimulates GIP secretion. From analysis of K cells isolated from GIP reporter mice, free fatty acid receptor GPR40 and GPR120 were highly expressed in K cells. GPR40/GPR120 double-knockout mice showed that GPR40 and GPR120 are essential for GIP secretion after fat ingestion.
GIPR-knockout mice are reported to be reduced fat mass and improved insulin sensitivity associated with aging. Therefore, GIP could be involved in fat accumulation and insulin resistance with aging. However, age-related changes of GIP secretion remain unclear. We found that aged mice showed hypersecretion of GIP under normal diet-fed condition. From analysis of K cells using GIP reporter mice, K cell number was increased in small intestine of aged mice. In aged mice, the mRNA expression levels of GIP and transcriptional factor pancreatic and duodenal homeobox-1 (Pdx1) were increased in sorted K cells. GIP mRNA expression and content were decreased in Pdx1 knockdown small intestine treated with intestine-specific gene transfer (iGT). Thus, Pdx1 positively regulates GIP mRNA and K cell number in small intestine. GIP hypersecretion with aging is possibly due to the increase in Pdx1 expression.
In conclusion, several molecules which are involved in GIP secretion can be identified from analysis of K cells isolated from GIP reporter mice.
S-2-5
Macro nutrients and long-term glucose-lowering effects of DPP-4 inhibitors in individuals with type 2 diabetes The incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagonlike peptide-1 (GLP-1), are secreted from the gut in response to ingestion of various nutrients and enhance insulin secretion glucose dependently to exert their glucose-lowering effects. GLP-1 also ameliorates postprandial glucose excursions by inhibiting glucagon secretion and delaying gastric emptying, while GIP has a possibility to worsen glycemic control by facilitating fat accumulation in response to chronic high-fat intake and enhancing insulin resistance. Dipeptidyl-peptidase-4 (DPP-4) inhibitors exert HbA1c-lowering effects by inhibiting DPP-4-mediated degradation of GIP and GLP-1. Previously, we reported that HbA1c-lowering effects of DPP-4 inhibitors are enhanced by fish intake, presumably because the nutrients in fish promote GLP-1 secretion (J Diabetes Investig; 3(5):464-7, 2012).
Furthermore, we recently found that long-term HbA1c-lowering effects of DPP-4 inhibitors, but not metformin, were also affected by dietary habits. Among those receiving DPP-4 inhibitors for 1 year without any prescription change, some of patients showed deteriorated HbA1c-lowering effects of DPP-4 inhibitors along with subtle but significant increase of body weight. The patients with deteriorated HbA1c-lowering effects of DPP-4 inhibitors tend to have significantly higher total energy intake and fat intake, while carbohydrate and protein intake were similar to those of other patients. The patients also had significantly higher intake of saturated and monounsaturated fats but not polyunsaturated fats. A stepwise multiple regression analysis showed that DHbA1c (1-0.5 year) that reflects deterioration of HbA1c-lowering effects of DPP-4 inhibitors was independently correlated with saturated fat intake (B = 0.032, SE=0.010, P < 0.01). These findings were specific to DPP-4 inhibitors and were not confirmed in patients receiving metformin for 1 year without any prescription change. It was known that saturated fats enhance robust secretion of GIP, which facilitates fat accumulation and subsequently enhances insulin resistance. Thus, enhancement of GIP function on adipose tissue by chronic fat intake could contribute to deterioration of HbA1c-lowering effects of DPP-4 inhibitors.
S-2-6
The genetic markers for the effect of GLP-1 analogue in patients with poorly controlled type 2 diabetes Type 2 diabetes patients have been proved to have decreased glucagon-like peptide-1 (GLP-1) levels. GLP-1 analogue therapy is associated with improved glycemic control by boosting GLP-1 levels. Nevertheless, the clinical effects are in great diversity for poorly controlled type 2 diabetes patients. Because of the heterogeneous blood glucose status, we have to optimize the insulin therapy in the first priority. Continuous subcutaneous insulin infusion (CSII) or insulin pump is a viable choice for patients with DM who want close-to-physiologic insulin treatment. By means of the insulin pump therapy, standardized sugar control profile in type 2 DM patients could be achieved in a short time. We can further evaluate the clinical response under GLP-1 analogue or not. We firstly set up the model of intensive insulin therapy with CSII for patients with T2D and assessment of GLP-1 analogue response. Secondly, we designed a randomized, two-regimen, comparative study to evaluate the blood glucose regulation and safety of GLP-1 analogue adding on the CSII therapy in poorly controlled T2D patients in Taiwan. In the GLP-1 analogue group, there was a significant higher standard deviation of plasma glucose (SDPG). The adiponectin level was significantly increased with exenatide added on. In analyzing the polymorphisms of GLP1R gene and response to GLP-1 analogue by whole exon sequencing, we found that the single nucleotide polymorphism (SNP) of rs761386 in GLP1R gene was significantly associated with changes in the standard deviation of plasma glucose. Performing whole genome methylation assay in poorly controlled T2D patients receiving GLP-1 analogue. Altered metabolism has been implicated in the pathogenesis of b-cell failure in type 2 diabetes. Several clinical studies have confirmed the positive role of plasma and tissue levels of several ceramide species in the inflammatory and stress responses that mediate type 2 diabetes. However, the inflammatory targets of ceramide remain to be identified. Recently, we reported that CD36, a class B scavenger receptor, initiates glucolipotoxicity-induced beta-cell dysfunction and is involved in the pathogenesis of type 2 diabetes. Here, we investigated the role of CD36-dependent Vav2 signaling and its role in ceramide-induced b-cell inflammation using INS-1 cells treated with C2-ceramide (N-acetyl-sphingosine). Exposure of INS-1 cells to C2 ceramide (50 µM) induced a time-dependent increase in Src-mediated Vav2 tyrosine phosphorylation, which activated GEF activity and induced active Rac1-GTP expression. In turn, Rac1-GTP activation enhanced NADPH oxidase activity and resulted in 4.5-fold increase in ROS production. In addition, NADPH oxidase activity potentiated C2 ceramide-induced nuclear factor NF-kB transcription, which was found to be associated with TXNIP upregulation and suppression of thioredoxin activity. Interestingly, pharmacological inhibition of CD36 by sulfo-N-succinimidyl oleate (SSO) blocked C2 ceramide-induced Src activation and reduced Vav2 GEF activity by inhibiting Vav2 tyrosine phosphorylation. Furthermore, downregulation of active Rac1-GTP resulted in decreased NADPH oxidase activity. Under the same conditions, nuclear factor NF-kB transcription was strongly inhibited. Moreover, CD36 inhibition downregulated TXNIP expression and promoted thioredoxin activity. Finally, inhibition of CD36 by SSO or Src activation by SU6656 reduced INS-1 cell apoptosis. Taken together, our results revealed a novel role for CD36 during the early molecular events leading to Vav2-mediated Rac1-GTP-NADPH oxidase complex activation, which in turn contributes to ceramide-induced pathogenesis of pancreatic beta-cell dysfunction and failure.
S-3-4
Regulation of compensatory b-cell proliferation by vagal nerve signals
J. Imai Tohoku University Graduate School of Medicine
In insulin-resistant states such as obesity, pancreatic b cells undergo compensatory proliferation and secrete more insulin to prevent blood glucose elevation. Previously, we discovered that pancreatic vagal nerve signals, elicited by activation of the hepatic extracellular signal-regulated kinase (ERK) pathway, play critical roles in triggering compensatory b-cell proliferation during obesity development. We recently recognized that, as part of this inter-organ network system, vagal nerve signals induce compensatory b-cell proliferation through a Forkhead box protein M1 (FoxM1)-dependent mechanism. Anatomically, preganglionic vagal nerves terminate at the pancreatic parasympathetic ganglion (PPG), and signals are likely transmitted to postganglionic neurons. Therefore, we attempted to anatomically analyze PPG using the recently developed tissue clearing method CUBIC. These analyses showed that PPG is frequently located adjacent to pancreatic islets, suggesting significant roles of the vagal nerve system in b-cell physiology. Thus, based on these findings, we explored the molecular mechanism(s) by which vagal nerve signals enhance b-cell proliferation. FoxM1 and its target genes were upregulated in pancreatic islets of hepatic ERK-activated mice or obese mice, and b-cell proliferation induced by either hepatic ERK activation or obesity was completely blocked in b-cell-specific FoxM1 knockout mice (FoxM1bKO mice). Either suppression of the hepatic ERK pathway or pancreatic vagotomy completely blocked activation of b-cell FoxM1 and thereby suppressed b-cell mass increases in mice during obesity development. Furthermore, combined treatment of pancreatic islets with pancreatic vagal nerve-producing factors, such as acetylcholine and PACAP/VIP, significantly upregulated the expressions of FoxM1-related genes and enhanced b-cell proliferation, and these effects were completely abolished in islets from FoxM1bKO mice. Our results demonstrate how vagal nerve signals induce compensatory b-cell proliferation in obesity settings. Manipulating this mechanism may lead to the development of novel therapeutic strategies aimed at increasing b-cell mass.
S-3-6
Adaptive b-cell proliferation through the FoxM1/PLK1/CENP-A pathway J. Shirakawa Department of Endocrinology and Metabolism, Yokohama City University, Japan
Investigation of cell cycle kinetics in mammalian pancreatic b cells has mostly focused on transition from the quiescent (G0) to G1 phase. However, the mechanisms that regulate transition in subsequent phases of the cell cycle in b cells are obscure. Our studies on gene expression microarray analysis of b cells derived from b-cell-specific insulin receptor knockout (bIRKO) mice revealed several novel targets of insulin receptor signaling. In the present study, we focused on a gene, centromere protein A (CENP-A), a histone H3 variant critically involved in G2/M-phase cell cycle control that was significantly downregulated (>95% compared to control) in the bIRKO group. Furthermore, the expression of pololike kinase-1 (PLK1), a key factor that initiates CENP-A deposition in the centromere, was also attenuated in bIRKO cells. We validated the significant reduction in expression of CENP-A in bIRKO mouse islets by comparing with wildtype mouse islets. Treatment of wild-type mouse islets or human islets with exogenous insulin increased CENP-A and PLK1 expression. Receptor-mediated insulin signaling promotes DNA-binding activity of FoxM1 to regulate expression of CENP-A and PLK1 by modulating cyclin-dependent kinase-1/2. CENP-A deposition at the centromere is augmented by PLK1 to promote mitosis, while knocking down CENP-A limits b-cell proliferation and survival. Inducible b-cellspecific CENP-A knockout mice (bCenpaKO) developed glucose intolerance, and decreased b-cell proliferation and mass in response to aging, pregnancy, or highfat diet-induced chronic insulin resistance. CENP-A-deficient b cells from bCenpaKO mice demonstrated significant decrease in cell proliferation in response to a glucokinase activator (GKA) and reduced b-cell mass expansion and proliferation in response to acute insulin resistance induced by S961 (insulin receptor antagonist). Insulin-stimulated CENP-A/PLK1 protein expression is blunted in islets from patients with type 2 diabetes. These data implicate the FoxM1/PLK1/ CENP-A pathway-regulated mitotic cell cycle progression as an essential component in the b-cell adaptation to delay and/or prevent progression to diabetes.
Abstracts
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The way of beta-cell protection: glucocentric approach Y. M. Cho Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea Type 2 diabetes is characterized by relentless decline of beta-cell function, which is clinically manifested by gradual increase in HbA1c despite standards of care according to current treatment guidelines. The pathogenesis of beta-cell dysfunction in type 2 diabetes is very complex and multifactorial. Genetic predisposition to beta-cell dysfunction is very important. However, there is no definitive target agent to address this problem except some types of genetic diabetes such as MODY and neonatal diabetes. In general, glucose toxicity is regarded as a wellestablished mechanism of progressive decline of beta-cell function in type 2 diabetes. Early intensive insulin therapy to normalize blood glucose levels may lead to remission of type 2 diabetes. Oral anti-diabetes agents also induce the remission of type 2 diabetes, when they are introduced early at the time of the diagnosis of type 2 diabetes. GLP-1 can restore first-phase insulin secretion or normal beta-cell glucose sensitivity in patients with type 2 diabetes. Recently, we showed that the beta-cell function can be improved in patients with type 2 diabetes by alleviating hyperglycemia with SGLT2 inhibitor. Therefore, various methods that can ameliorate hyperglycemia may lead to improvement of beta-cell function in patients with type 2 diabetes, which indicates that a glucocentric approach is important to protect beta cells from further functional decline.
S-4-1
The role of FoxO1 in the differentiation of human embryonic stem cells into islet b cells
W. Rui Department of Endocrinology and Metabolism, Peking University Third Hospital
BACKGROUND AND AIMS: Differentiation of human embryonic stem cells (hESCs) into islet b cells may be one of the most promising strategies to reconstruct pancreatic b-cell function. However, there are a variety of problems in the current differentiation schemes, such as immaturity of derived b cells, the unclear mechanisms of differentiation and maturation. Therefore, it is necessary to clarify the molecular mechanism of the differentiation process, which can be much helpful to gain more mature islet b cells. In this study, we aimed to explore the roles of FoxO1 in this differentiation process and the underlying mechanism. MATERIALS AND METHODS:
1. The hESCs were differentiated into the insulin-producing cells (IPCs) based on the definitive endoderm (DE) stepwise differentiation protocol. The expression of differentiation stage-specific markers and the insulin secretion capability of IPCs were analyzed by using real-time PCR, immunofluorescence and ELISA, respectively. The dynamic change of expression and localization of FoxO1 was detected by PCR and western blot. 2. The stage 3 (S3) cells (pancreatic progenitor), derived from hESCs during the IPC differentiation, were infected with the FoxO1-knockdown or FoxO1-overexpression lentiviral vectors, or incubated with a FoxO1 inhibitor AS1842856. The respective lentiviral empty vectors or solvent dimethyl sulphoxide were served as the negative controls. The expression of differentiation markers was detected by real-time PCR. The glucose-stimulated insulin release response was evaluated in the IPCs by ELISA. 3. To investigate the possible mechanism of FoxO1 during the hESCs differentiation into the IPCs, we detect the nuclear/cytoplasmic localization of FoxO1 and pancreatic important transcriptional factor Pdx1 by using immunofluorescence and western blot analyses. Furthermore, the S3 cells were collected, and the targets of FoxO1 were analyzed by chromatin immunoprecipitation and sequencing assay. RESULTS:
1. hESCs could be induced to differentiate into IPCs by using DE stepwise protocol. The expression of pluripotency marker Oct4 decreased, while the levels of pancreatic b-cell differentiation markers such as Pdx1 and insulin increased during the differentiation stages. We noted that the mRNA and protein levels of FoxO1 were sustainable and stable, while cytoplasmic phosphorylated FoxO1 (p-FoxO1) protein level increased and nuclear FoxO1 protein level decreased as the differentiation processed. 
S-4-5
The role of pancreatic-derived factor in glucose and lipid metabolism
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
Pancreatic-derived factor(PANDER, also named as FAM3B) is a cytokine identified in 2002, which is secreted from a and b cells of pancreatic islets. Increasing evidence suggests that it may serve a hormonal function related to glycemic and lipid metabolism. The initial evaluation indicated PANDER induced apoptosis of b cells of pancreatic islets. Recent researches showed that PANDER specifically binded to the liver cell membranes.
[18F]FB-PANDER dose dependently binded to HepG2, GLUTag membranes. And liver, pancreas and intestine had the higher original accumulations of radioactivity than brain, heart, spleen, muscle and testis using mice PET-CT scan. Studies have shown that PANDER promoted hepatic glucose production, lipogenesis and resulted in hepatic insulin resistance. In cultured GLUTag cell line, we found that PANDER exposure led to decreased glu mRNA expression and total GLP-1 secretion in a dose-and time-dependent manner. Meanwhile, PANDER reduced p-IRS-1, PI3K, p-Akt , p-GSK3b protein level in cytoplasm and b-catenin level in nucleus of GLUTag cells. In mice transfected with Ad-PANDER, we observed a significant decrease of triglyceride (TG) content in both liver and adipose tissue, as well as a significant decrease of free fatty acid (FFA) content of adipose tissue. Also, the mRNA of glu gene of mice intestine, the serum total GLP-1 and active GLP-1 level significantly decreased. Furthermore, p-IRS-1, PI3K, p-Akt, p-GSK3b protein level in cytoplasm and bcatenin level in nucleus reduced in intestine of Ad-PANDER-transfected mice. In a cohort of 212 individuals, the plasma PANDER level was increased with the number of Metabolic Syndrome components and correlated with metabolic score. Multivariable logistic regression analysis has indicated that circulating PANDER was associated with an increased risk ratio of impaired glucose tolerance or diabetes mellitus (odds ratio 2.22, 95% confidence interval 1.15-4.42, P = 0.018) after adjustment of the other possible confounders. All together, those data have suggested that PANDER has played a role in the glucose and lipid metabolism and is associated with an increased risk of metabolic disorder, although the mechanisms by which this occurs remain to be elucidated.
Defective glucose-stimulated insulin secretion (GSIS) is a key characteristic of type 2 diabetes at late stage. Previous studies have shown that the adaptor protein APPL1 potentiates first-phase GSIS by modulating the exocytotic machinery SNARE proteins in an Akt-dependent manner, whereas the role of its close homolog APPL2 in pancreatic b cells remains obscure. Here, we show that APPL2 regulates GSIS in a distinct mechanism from APPL1. Mice lacking APPL2 in pancreatic b cells displayed a dramatic reduction of first-phase and second-phase GSIS, resulting in glucose intolerance. APPL2 deficiency had no effect on glucose metabolism, calcium signaling and SNARE protein expression but impaired glucose-stimulated F-actin (Filamentous actin) remodeling in pancreatic islets. Defective GSIS in the islets lacking APPL2 was reserved by the Factin depolymerizing drug Latrunculin A. Further analysis revealed that RNAimediated knockdown of APPL2 largely abolishes glucose-stimulated activation of Rac1, a small GTPase is known to regulate F-actin remodeling in pancreatic b cells. Therefore, deciphering the role of APPL2 in F-actin remodeling might provide a potential therapeutic target for type 2 diabetes by continuously evoking first-and second-phase GSIS.
PO3-3
Correlation between IGF-II and Foxo1 in pancreatic adult stem cell differentiation
C. Sun The First Hospital of Jilin University
To investigate the mechanism of rapamycin inhibiting the differentiation and proliferation of newborn porcine pancreatic adult stem cells and to explore the therapeutic methods that can effectively reduce the side effects of rapamycin.
Porcine NPCCs were treated with rapamycin alone or in combination with IGF-II, and the caspase-3 and H3-thymidine uptake assays were performed to detect apoptosis and proliferation. The expression of Insulin, PDX-1,NeuroD/ Beta2 and Foxo1, a downstream transcription factor of IGFII, was analyzed by RT-PCR and Western blot to evaluate the differentiation ability of pancreatic adult stem cells.
The NPCCs treated with rapamycin inhibited the proliferation of b cells, increased the apoptosis, reduced the insulin secretion, inhibited the expression of PDX-1 and NeuroD/Beta2, and decreased the expression of IGF-II Foxol expression and induction of Foxol from the cytoplasm to the nucleus of the ectopic. The combined treatment of rapamycin and IGF-II can reduce the side effects of rapamycin, inhibit the decrease of b-cell number and insulin content, repair the expression of insulin, PDX-1, NeuroD/Beta2, inhibit Foxo1 expression and intracellular ectopic.
Aberrant expression of IGF-II and Foxol genes is the key inducing factor of rapamycin inhibiting the proliferation and differentiation of NPCCs, and IGF-II treatment can effectively reduce the side effects of rapamycin on NPCC differentiation.
PO1-4
Downregulation of HuD by lower zinc in diabetic pancreatic b cells Pancreatic b-cell failure is the major pathophysiologic abnormalities of type 2 diabetes (T2DM).
HuD is a RNA-binding protein expressed in neuron and pancreatic b cells and plays diverse roles in regulations of insulin synthesis, autophagosome formation, and triglyceride (TG) synthesis.
However, the regulatory mechanism governing HuD expression has not been yet elucidated. Here, we present evidence that zinc ion is a novel
PO4-1
Bone quality in Chinese postmenopausal women with type 2 diabetesimpact of dipeptidyl peptidase-4 inhibitor usage OBJECTIVES: To compare the bone quality in type 2 diabetes (T2D) subjects to those without T2D and evaluate the impact of dipeptidyl peptidase-4 inhibitor (DPP4-i) usage on bone quality in T2D subjects, in view of the potential effects of DPP4 and the incretins on bone biology. METHODS: We conducted a cross-sectional study of post-menopausal women with T2D subjects recruited from the Hong Kong West Diabetes Registry and nondiabetic subjects from the Hong Kong Cardiovascular Risk Factor Prevalence Study, from November 2016 to June 2018. Subjects with fasting glucose 5.6-6.9 mmol/L, 2 hours post-load glucose 7.8-11.0 mmol/L in oral glucose tolerance test, or HbA1c 5.7-6.4% were classified as pre-diabetes and those with normal glucose tolerance as euglycaemia. Bone mineral density (BMD), vertebral fracture assessment (VFA), and trabecular bone score (TBS) were measured by dual Xray absorptiometry. BMD and TBS in DPP4-i users and non-users with T2D were compared. RESULTS: Three hundred and sixty subjects were studied: 98 with euglycaemia, 154 with pre-diabetes, and 108 with T2D. Using euglycaemia subjects as reference, prediabetes and T2D subjects were significantly older (euglycaemia 60.0 -4.4, prediabetes 61.8 -5.5, and T2D 63.1 -5.5 years, p < 0.001) and heavier (euglycaemia 56.1 -9.2, pre-diabetes 60.1 -10.1, and T2D 62.0 -10.5 kg, P < 0.001). Lumbar spine (LS) BMD among T2D subjects was significantly higher than subjects with euglycaemia after adjustment for age, height and weight (0.942 g/cm2 vs 0.876 g/cm2, P = 0.001). TBS among T2D subjects, however, was significantly lower than those with euglycaemia after adjustment for age, height, weight and LS BMD (1.26 vs 1.30, P < 0.001). Among T2D subjects, 47 were DPP4-i users and 61 were non-users. Mean duration of DPP4i usage was 3.1 -2.4 years. Age, height, weight, fragility fracture prevalence, HbA1c, duration of diabetes, and frequency of usage of other oral anti-diabetic agents were not significantly different between the two groups. More insulin usage was found among DPP4-i non-users. After adjustment for insulin usage, there was no difference in LS BMD or TBS between DPP4-i users and non-users. CONCLUSIONS: Hong Kong Chinese subjects with T2D had lower TBS, an indirect index of bone microarchitecture, but higher BMD when compared with those with euglycaemia. DPP4-i usage, however, did not have significant impact on BMD or TBS among T2D subjects. 
PO6-5
Development of non-invasive monitoring method using direct linking of Ferumoxytol to surface of PEGylated Islet PURPOSE: Islet transplantation is promising therapy for type 1 DM patients. However, this procedure is still not ideal because a large proportion of transplanted islets are rapidly eliminated from the recipients due to immune reactions and non-specific inflammation. Therefore, there is a strong clinical need for real-time assessment of functioning islet mass in the recipients of islet grafts, because the majority of islet injury in clinical islet transplantation takes place before changes in recipient glycemic levels become apparent. The magnetic resonance imaging (MRI) is one of noninvasive monitoring methods. Contrast agent is very important to visualization on MRI. We previously reported the feasibility of islet magnetic resonance imaging (MRI) using ferumoxytol, which is the only clinically available ultrasmall superparamagnetic iron oxide. However, the labeling efficacy was not sufficient for its clinical use in islet transplantation. We aimed to evaluate the feasibility of islet MRI using direct linking of ferumoxytol to islet surface through PEGylation. METHOD: Islets were labeled by ferumoxytol-heparin-PEG and compared function and viability. Efficacy of labeling with ferumoxytol-heparin-PEGylation and ferumoxytol alone was assessed in both ex vivo and in vivo models. RESULTS: Labeling of islets with up to 2% ferumoxytol-heparin-PEG did maintained viability and function of islet. The labeling intensity in the ex vivo MRI of ferumoxytol-heparin-PEGylated islets was stronger than islets labeled with ferumoxytol alone. In syngeneic renal subcapsular islet transplantation, labeling with ferumoxytol-heparin-PEGylation showed better in vivo labeling efficacy than that of islets labeled with ferumoxytol alone. CONCLUSION: The labeling efficacy of ferumoxytol-heparin-PEGylated islets improved more than to ferumoxytol alone. This labeling method suggests the possibility of noninvasive monitoring in clinical islet transplantation.
PO6-1
Oligo (Alanine)-modified methoxy-poly (ethylene glycol) hydrogels: an in situ gelling system for MIN6 cell cultivation and transplantation A cell scaffold is an important issue in cell therapy where transplantation of functional tissues is required. Ideal scaffold materials should be able to deliver to any location with minimal invasion and maintain graft function for a long period. Thermosensitive hydrogels are capable of gelling at body temperature by physical interactions from solution state. In previous study, a 3D cell culture matrix was constructed by warming a cell-containing mPEG-poly(alanine) aqueous solution at room temperature to 37°C. Due to their unique characteristics, the hydrogels have been demonstrated to support good cell viability, proliferation, and as a source for delivery of protein growth factors. The MIN6 cell line derived from a mouse insulinoma is one of a few cell lines that display characteristics of pancreatic b cells, such as insulin secretion in response to glucose stimulation. The focus of the current study is to use mPEGpoly(alanine) hydrogels to encapsulate MIN6 cell clusters in order to validate the use of these hydrogels for cell therapy in diabetes treatment. Proper mixing of growth factors or cells with the copolymer solution allows them to be uniformly distributed within the structure after in situ gelation. It is also possible to mold the scaffold in situ to attain the desired location to fit the b-cell survival.
According to the in vitro study, after culturing for 14 days, the viability of MIN6 cells in mPEG-Ala hydrogel was comparable with those in medium, either assayed by MTT or LIVE/DEAD. Furthermore, static incubation showed that both had comparable insulin secretion in response to glucose stimulation. For in vivo experiments, positive IVIS images and insulin staining of tissue histology were observed up to 41 days after transplantation. Meanwhile, the graft of CSPIOlabeled MIN6 cells was visualized on Magnetic Resonance (MR) scans as distinct hypointense spots located at the transplantation site at days 6 and 20. These results indicate that subcutaneous transplantation of MIN6 cells embedded in temperature-sensitive mPEG-Ala hydrogels is feasible. Moreover, the IVIS and MR imaging are useful tools for detecting and monitoring cells at the subcutaneous site.
PP1-3
Function of skeletal muscle mitochondria during insulin resistance
H. Wang The First Hospital of Jilin University
BACKGROUND: This study aims to investigate the functional changes in skeletal muscle mitochondria during insulin resistance (IR). METHODS: Insulin resistance, type 1 diabetes mellitus (T1DM), and type 2 diabetes mellitus (T2DM) models were established in rat. Insulin resistance status was evaluated using hyperinsulinemia-glucose clamp experiments. Skeletal muscle mitochondria were extracted, and the respiratory function and fatty acid b-oxidation were measured. RESULTS: Animal models were successfully established, and insulin resistance and type 2 diabetes mellitus rats exhibited significantly increased body weight compared with normal control and type 1 diabetes mellitus rates (P < 0.05). Upon successful establishment of rat models, type 1 diabetes mellitus and type 2 diabetes mellitus rats showed remarkably higher fasting blood glucose than did normal control and insulin resistance rats (P < 0.05). The differences in glucose infusion rates for four groups of rats were statistically significant (P < 0.001). The differences in skeletal muscle mitochondrial respiratory control rate for four groups of rats were statistically significant (P = 0.025). The differences in skeletal muscle mitochondrial carnitine palmitoyl transferase-1 (CPT-1) expression for four groups of rats were also statistically significant (P = 0.02). Finally, the differences in skeletal muscle mitochondrial carnitine palmitoyl transferase-1 enzyme activity were nonsignificant. CONCLUSION: Under insulin resistance conditions, skeletal muscle showed impaired mitochondrial respiratory function and decreased carnitine palmitoyl transferase-1 protein expression. The skeletal muscle mitochondrial dysfunction was closely related with insulin resistance. The mitochondrial respiratory function and fatty acid b-oxidation activity for skeletal muscle were damaged at the insulin resistance state, but did not worsen under high insulin conditions.
PP1-7
Modulation of adipocyte differentiation by MST1-mediated phosphorylation of miRNA-binding protein AUF1 mRNA decay can be regulated is the MST1 (Mammalian Ste20-like kinase 1) pathway, where MST1 controls the activity of RNA-binding proteins whose binding ultimately regulates mature miRNA abundance. Through the action of those miRNAs, MST1 also ultimately controls miRNA-mediated mRNA decay. Previously, we have shown that the phosphorylation of Dcp2 by Ste20 in yeast and eIF4E by MST1 in mammals inhibits mRNA decay and translation, suggesting that MST1 has a certain role in posttranscriptional gene regulation. Here, we identified novel signaling pathways wherein MST1 is activated in adipocytes to modulate the abundance of mature miRNAs and their target mRNAs by differential phosphorylation of MST1's target miRNA-binding proteins. The consequences of these phosphorylation events include upregulation of specific mature miRNA, suppression of abundance of mRNAs targeted by those miRNAs, and suppression of adipocyte differentiation. Our findings indicate that MST1 signaling pathways control the stability of target mRNAs by differential phosphorylation of miRNA-binding proteins and implicate that MST1 is a crucial factor for the degradation of mature miRNAs during adipocyte differentiation.
mRNA degradation is an important step in post-transcriptional gene expression regulation during cellular proliferation and differentiation. One way in which mRNA decay can be regulated is the MST1 (Mammalian Ste20-like kinase 1) pathway, where MST1 controls the activity of RNA-binding proteins whose binding ultimately regulates mature miRNA abundance. Through the action of those miRNAs, MST1 also ultimately controls miRNA-mediated mRNA decay. Previously, we have shown that the phosphorylation of Dcp2 by Ste20 in yeast and eIF4E by MST1 in mammals inhibits mRNA decay and translation, suggesting that MST1 has a certain role in posttranscriptional gene regulation. Here, we identified novel signaling pathways wherein MST1 is activated in adipocytes to modulate the abundance of mature miRNAs and their target mRNAs by differential phosphorylation of MST1's target miRNA-binding proteins. The consequences of these phosphorylation events include upregulation of specific mature miRNA, suppression of abundance of mRNAs targeted by those miRNAs, and suppression of adipocyte differentiation. Our findings indicate that MST1 signaling pathways control the stability of target mRNAs by differential phosphorylation of miRNA-binding proteins and implicate that MST1 is a crucial factor for the degradation of mature miRNAs during adipocyte differentiation.
PO5-1
Effects of imeglimin on insulin secretion, beta-cell proliferation, or apoptosis in mouse islets Imeglimin, an anti-hyperglycemic agent, is thought to have beneficial effects on mitochondrial function of the liver, skeletal muscle, and pancreatic beta cells in type 2 diabetes. However, the molecular mechanisms of imeglimin action have been still unknown. The aim of this study was to clarify the effects of imeglimin on insulin secretion, beta-cell proliferation, or beta-cell apoptosis in mouse islets. Mouse islets were isolated from 8-to 10-week-old male C57BL/6J wild-type mice. Glucose-induced insulin secretion from isolated islets was examined at concentrations of 3.9, 11.1, or 16.7 mM glucose in the presence or absence of imeglimin (0.1 mM or 1.0 mM) or liraglutide (100 nM). Liraglutide increased glucose-induced insulin secretion from islets under 11.1 mM glucose (4.2-fold, n = 5, P < 0.05) or 16.7 mM glucose (4.1-fold, n = 5, P < 0.01). Treatment of islets with 1.0 mM, but not 0.1 mM, imeglimin significantly increased insulin release in response to glucose (2.1-fold, n = 5, P < 0.01 at 11.1 mM glucose, 1.9-fold, n = 5, P < 0.05 at 16.7 mM glucose). Both liraglutide and imeglimin had no effect on the insulin content in the islets compared to control. Treatment with a combination of liraglutide and 1.0 mM imeglimin did not show an additional increase in insulin secretion compared to the treatment with liraglutide alone (1.1-fold, n = 6, P = 0.53 at 11.1 mM glucose). beta-cell proliferation was evaluated by the proportion of EdU-incorporated insulin-positive beta cells in islet sections. TUNEL staining was performed to assess beta-cell apoptosis. Liraglutide and 1.0 mM imeglimin, but not 0.1 mM imeglimin, significantly increased EdU-incorporated proliferating beta cells in the islets under 11.1 mM glucose (1.02% in vehicle control; 2.21% in liraglutide, n = 5, P < 0.01 vs. vehicle; 1.46% in 1.0 mM imeglimin, n = 5, P < 0.01 vs. vehicle). The proportion of TUNEL-positive apoptotic beta cell were increased by high glucose (0.62% in 3.9 mM glucose, 1.07% in 11.1 mM glucose, n = 4, P < 0.05). Liraglutide and 1.0 mM imeglimin prevented beta-cell apoptosis induced by high glucose (57% of control in liraglutide, n = 4, P = 0.07; 32% of control in imeglimin, n = 4,OBJECTIVE: To investigate the thyroid hormone changes in patients with newly diagnosed and previously diagnosed diabetes. METHODS: Participants aged from 20 to 79 with the negative thyroid autoantibodies and free of a history of thyroid disease were recruited from candidates undergoing health examination in West China Hospital, Sichuan University in 2016. Participants were divided into the groups of diabetes and the non-diabetes according to the medical history, fasting serum glucose and HbA1c. The group of diabetes was further divided into the group of newly diagnosed diabetes (NDD) and the group of previously diagnosed diabetes (PDD). Independent ttest and the multivariate Logistic regression were used in comparing the thyroid stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3) and FT4/FT3 ratios between groups. RESULTS: We recruited 32,557 participants, 7% and 3.63% of which were diabetes and NDD, respectively. FT4 and FT4/FT3 in the group of diabetes were higher than those in the group of non-diabetes (FT4: 17.09 -2. 
PP2-6
Methanol poisoning in a patient with type 2 diabetes mellitus : a case report Methanol poisoning in diabetic patient can present with symptoms of diabetic ketoacidosis in diabetes patients. This case warns us not to neglect the possible existence of other problems in patients with obvious diseases. We describe a case that matched the criteria for diabetic ketoacidosis and was treated according to the relevant guidelines and protocol. Although the acidosis was corrected quickly, the patient experienced a progressive decline in visual acuity. Review of the patient's medical records revealed a history of drinking self-prepared alcoholic drinks containing a high concentration of methanol. After treatments, the patient's vital signs were stable, and his vital organ function was protected. However, the blindness was not improved. The lesson of this report is that although it is to be hoped that methanol consumption is uncommon, it should be recognized as a condition that can mimic DKA. For suspected cases, clinicians should perform a thorough history inquiry regarding potential exposure sources. Early recognition and treatment is essential for the management of methanol intoxication and minimization of morbidity and mortality. Using RT-PCR and western blot, we detected expression of the GPR40, a G protein-coupled receptor recently identified as a receptor for free fatty acids and TZDs in INS-1 cells. GPR40 mRNA and protein levels were increased by 80 and 60%, but not in cells transfected with GPR40 or PPARc shRNA. GPR40 overexpression without TZD led to a significantly enhanced insulin secretion in response to glucose, and GPR40 activity, measured by fluorescence spectroscopy, was also significantly increased. The increase of GPR40 by TZDs was associated with the increased glucagon-like peptide-1 (GLP-1) sensitivity in INS-1 cells. TZDs also showed protective effects against the palmitateinduced aggravation in insulin secretion. CONCLUSIONS: TZDs significantly increased the incretin sensitivity and protected against the lipotoxicity through the stimulation of GPR40 expression in pancreatic b-cell.
PO2-6
Activation of GLP-1 receptor inhibits hepatocarcinogenesis through CAMP-PKA-EGFR-STAT3 axis Type 2 diabetes contributes to the development of hepatocellular carcinoma (HCC), shown by the accumulating evidences from both clinical and experimental studies. Exendin-4 (Ex-4), a potent anti-diabetes drug targeting glucagon-like peptide-1 receptor (GLP-1R), was reported to protect the liver from non-alcoholic fatty liver disease (NAFLD). However, it is unknown about the Ex-4 function and GLP-1R signaling in HCC. In this study, we investigated the effect of Ex-4 in diethylnitrosamine (DEN)-induced HCC mice consuming normal control or high-fat high carbohydrate diet. Ex-4 treatment significantly improved obesity-induced hyperglycemia and hyperlipidemia. Furthermore, Ex-4 administration dramatically reduced HCC multiplicity and tumor weight in DEN-treated mice, in which suppressed proliferation and induced apoptosis were confined to tumor cells. In addition, it is found that high GLP-1R expression, subsequential activation of cyclic AMP (cAMP) and protein kinase A (PKA) are critical to the tumor suppressive effects of Ex-4. The tumor inhibitory effects of Ex-4 were only observed in GLP-1R-abundant human hepatoma cell lines. Inhibition of PKA activity attenuated the growth suppressive effect of Ex-4 in hepatoma cells. Importantly, Ex-4 also downregulated epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3), which are the downstream effectors of cAMPPKA signaling, resulting in suppression of multiple STAT3-targeted pro-oncogenes including c-Myc, cyclin D1, survivin, Bcl-2 and Bcl-xl. Besides the regulation of oncogene signaling, we also found Ex-4 effectively suppressed inflammatory and fibrotic phenotypes in mice fed with methionine-choline-deficient (MCD) diet and choline-deficient ethionine-supplemented (CDE) diet, respectively. MCD diet-induced inflammatory symptoms were effectively improved by Ex-4 treatment, evidenced by reduced lobular inflammation, TNF-alpha and MCP1 mRNA expressions. In CDE diet induced liver fibrosis model, Ex-4 treatment remarkably alleviated hepatic steatosis and fibrosis and diminished the hepatic progenitor cell amount. In summary, Ex-4 elicits protective functions against DEN induced HCC through cAMP-PKA-EGFR-STAT3 signaling, suggesting Ex-4 administration as a novel approach to reduce HCC risk in diabetic patients. Long-chain fatty acid potentiates glucose-induced insulin secretion (GIIS) from pancreatic b cells via the activation of GPR40. Previous studies indicated that GPR40 agonist fasiglifam (fas) enhances Ca2 + release from the endoplasmic reticulum (ER) by activating inositol 1,4,5-triphosphate (IP3) receptor and augments GIIS. However, it remains unclear how the enhanced Ca2 + release from the ER is linked to GIIS potentiation. We hypothesized that ER Ca2 + sensor STIM1 senses decline of Ca2 + levels in the ER, translocates to the plasma membrane and triggers extracellular Ca2 + influx through Ca2 + -channel Orai1 to potentiate GIIS. To test the hypothesis, we examined the role of STIM1 in insulin-secreting MIN6 cells as well as in isolated islets derived from b-cellspecific STIM1-deficient mice.
PO1-2 ER
MIN6 cells were transfected with STIM1, IP3 receptor 1 (IP3R1) or scrambled siRNA, and were analyzed for insulin secretion and intracellular Ca2 + dynamics. MIN6 cells were also transfected with pEX-SP-YFP-STIM1 (23-685) to monitor intracellular trafficking of STIM1 in response to glucose and fas. Isolated islets were obtained from b-cell-specific STIM1-deficient (bSTIM1 cKO) or C57BL6/J mice and were analyzed for insulin secretion. Xestospongin C and GSK7975A were used as inhibitors for IP3 receptor and Orai1, respectively. STIM1 or IP3R1 knockdown in MIN6 cells similarly abolished fas-mediated potentiation of GIIS, while they had little effect on GIIS itself. STIM1 knockdown in MIN6 cells also attenuated fas-induced elevation of intracellular Ca2 + levels. STIM1-YFP was rapidly translocated from the ER to the plasma membrane in response to fas. Fas-mediated potentiation of GIIS and increment of intracellular Ca2 + were also severely impaired in isolated islets from bSTIM1 cKO mice. In addition, fas-mediated potentiation of GIIS was severely impaired by Xestospongin C and GSK7975A.
STIM1 plays an important role in fas-mediated potentiation of GIIS, possibly by sensing decline of Ca2 + levels in the ER, translocating to the plasma membrane and triggering extracellular Ca2 + influx through Ca2 + channel Orai1.
PO5-2
The protective effect of KPS-29 on Thapsigargin-induced apoptosis in mouse pancreatic b-cell line MIN6 In this study, we examined the effect of kps-29 on thapsigargin-induced apoptosis in min6 cell. Thapsigargin treatment increased cleaved poly (ADP-ribose) polymerase (PARP) protein levels in a dose-and time-dependent manner. Pretreatment of cells with 10 lM kps-29 prevented thapsigargin-induced apoptosis, caspase PARP cleavage. Cells were treated with 1 lM thapsigargin for 24 h, and flow cytometry was utilized to assess apoptosis using annexin-V. Thapsigargin upregulated activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP) expression. This effect was suppressed by pretreatment with kps-29. In addition, kps-29-mediated inhibition of phosphorylation of c-Jun amino terminal kinase (JNK) attenuated thapsigargin-induced cleavage of PARP. Taken together, the present study demonstrates that kps-29 attenuates thapsigargin-induced apoptosis through downregulation of CHOP expression and inhibition of JNK activation.
PO1-5
Global and pancreatic beta-cell-specific Ogt deletion revealed multiple effects of O-glcNAcylation in glucose metabolism O-GlcNAcylation is one of the post-translational modifications that is characterized by the addition of N-acetylglucosamine to various proteins by O-GlcNAc transferase (Ogt) and serves as "an intracellular nutrient sensor" by modulating various cellular processes. Although it has been speculated that O-GlcNAcylation is associated with glucose metabolism, its exact roles in whole body glucose metabolism and the relationship with the pathogenesis of diabetes have not yet been fully elucidated. To examine the role of O-GlcNAcylation in glucose metabolism, tamoxifen-inducible global Ogt knockout mice were generated by crossbreeding Ogt-flox mice with R26-Cre-ERT2 mice. Pancreatic beta-cell-specific Ogt knockout mice were generated by crossbreeding Ogt-flox mice with Pdx1PB-CreERTM mice. Various metabolic phenotypes including glucose metabolism were evaluated in both models. To evaluate the relationship between OGlcNAcylation and the pathogenesis of diabetes, we performed immunohistochemical analysis of O-GlcNAcylation over time in pancreas of LETO (Control) and OLETF (Obese type 2 diabetes model) rats. Tamoxifen-inducible global Ogt knockout mice exhibited a lethal phenotype with severe weight loss, hypoglycemia and hypoproteinemia, although food intake was preserved. Moreover, pancreatic beta-cell-specific Ogt knockout mice displayed transient hypoglycemia associated with enhanced insulin secretion and accelerated adiposity, followed by subsequent hyperglycemia with insulin depletion accompanied by beta-cell apoptosis. In diabetic rat models, immunohistochemistry for O-GlcNAcylation (RL2) partially decreased in pancreatic islets of 50-week-old OLETF rats. In this study, we demonstrated that O-GlcNAcylation in adult mice is essential for survival and glucose homeostasis maintenance and is important for pancreatic beta-cell function and survival. Moreover, the result from diabetic rat model suggested a relationship between O-GlcNAcylation and diabetes. Our results provide new insights into O-GlcNAc biology and beta-cell physiology in glucose metabolism.
PP2-3
Role of adaptive and innate immunity in type 2 diabetes mellitus S. Yang Department of Endocrinology and Metabolism, the First Hospital of Jilin University, Changchun, Jilin, China Type 2 Diabetes Mellitus (T2DM) which is characterized by abnormally elevated levels of blood glucose due to impaired insulin secretion, glucose intolerance, and hyperglycemia has become a health burden worldwide. Nowadays, the pathogenesis of T2DM is considered to be linked to both innate and adaptive immune factors that are recognized as important etiological components in the development of insulin resistance. According to the recognition of the essential role of immune system in the progression of type 2 diabetes mellitus(T2DM), increasing number of issues focused on the effects produced by the abnormal differentiation of immune system. In patients with obesity or T2DM, there were changed proliferations of T cells and macrophages, impaired function of NK cells and B cells, which represented abnormal innate and adaptive immunity. Either the abnormality of innate immunity or adaptive immunity was involved in the progression of T2DM. Although previous studies revealed the functional involvement of T cells in T2DM, and the regulation of metabolism by the innate or adaptive immune system in the pathogenesis of T2DM, respectively, literature reviewing the relevant role of adaptive and innate immunity in the pathogenesis of T2DM in recent years still remains blank. In the current study, we reviewed the relevant research accordingly, purposing to provide new thought for the development of immune therapy for T2DM. A large body of evidence supported linkage between immune system and T2DM. It should be considered whether T2DM was an autoimmune disease due to the importance of inflammation in the development of insulin resistance, obesity and T2DM.
PP1-4
Loss of Epac2A KO enhances resistance to cold via leptin-mediated mechanism OBJECTIVE: Leptin is a critical hormone that links energy intake and storage to energy consumption. Non-obese humans and animals are responsive to exogenous leptin, which increases food satiety and energy consumption. In Epac2A KO mice, plasma leptin level is found to be higher as compared with wild-type mice (C57BL/6J, WT). Thus, we investigated whether Epac2A KO mice are resistant to cold ambient temperature. METHODS: Seven-week-old WT and Epac2A KO mice were placed in an individual incubator for a 72-hr period to 4℃. Body temperature was measured every 2 hrs throughout this period, after 72 hrs of cold exposure, mice were euthanized and tissues were harvested. Mice were individually caged during experiment and fed ad libitum with free access to tap water. All values are expressed as mean -SEM. Statistical analysis was performed by using SPSS. RESULTS: During cold exposure, Epac2a-KO mice better-maintained body temperature in response to cold stress, and the decrease in body temperature induced by cold exposure was smaller than that in WT mice. Serum creatine kinase concentrations in the two groups were not different, which is a parameter of compensatory shivering. The thermogenic genes uncoupling protein-1 (UCP-1) and peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1a) in interscapular brown adipose tissue, interscapular white adipose tissue and epididymal fat showed greater elevation in the KO mice. The KO mice also exhibited greater expression of type 2 deiodinase in the brown and white adipose tissues. Plasma levels of T3 and T4, and T3/T4 ratio were parallel to these results. The decrease in subcutaneous, epididymal, perirenal and retroperitoneal fat depots by cold stress was dramatically greater in the KO mice. CONCLUSION: Epac2A KO mice are more resistant to cold stress with mechanisms independent of shivering effects. A mechanism may be leptin-mediated increase in sympathetic nerve activity to promote adipocytic lipolysis and thermogenesis as well as thyroid hormonal signaling.
PO2-2
DPP-4 inhibitor teneligliptin attenuates high glucose-induced beta-cell dysfunction via a CAMP-sirt1 pathway Teneligliptin, a newer DPP-4 inhibitor provides a narrative clinical efficacy and oral tolerability with a unique chemical structure amongst currently available DPP-4 inhibitors. A very recent study shows that DPP-4 is expressed in human pancreatic beta cells and there is no study about the effect of Teneligliptin in the pancreatic beta cells. Herein, we investigated the direct effect of Teneligliptin, on beta-cell function and survival in response to high glucose conditions.
We subjected INS cells and human 1.1b4 pancreatic beta cells to high glucose (30 mM) for 48 hours in the absence or presence of DPP-4 inhibitor Teneligliptin. Insulin secretion was assessed by Millipore ELISA Kit. P66Shc phosphorylation and mitochondrial translocation were measured by western blot and immunofluorescent analysis. Reactive oxygen species were measured by using DCFDA. Apoptosis was determined by TUNEL In Situ cell death detection kit. The protein expression level of GLP1R, Sirt1, JNK and cleaved caspase-3 signaling and SERCA2B ubiquitination in response to high glucose was assessed by western blot analysis.
Exposure of INS-1 cells or human 1.1b4 pancreatic beta cells to high glucose (30 mM) downregulated GLP1R expression and induced beta-cell apoptosis. Interestingly, Teneligliptin treatment stabilized GLP1R protein and increased the intracellular cAMP production (P < 0.005) and potentiate glucose-stimulated insulin secretion (GSIS) (P < 0.05). In parallel, Teneligliptin treatment correlated with the upregulation of Sirt1 expression. Further, Teneligliptin treatment significantly decreased the high glucose-induced reactive oxygen species (ROS) production (P < 0.05) and reduce the JNK-mediated p66Shc serine 36 phosphorylation and its mitochondrial translocation and cleaved caspase-3 activation. Moreover, Teneligliptin counteracted the high glucose-induced ubiquitination of SERCA2b and lowers the ER stress markers. Interestingly, cAMP pathway inhibition by H89 (PKA inhibitor) blocked the teneligliptin protective effects against the high glucose-induced beta-cell apoptosis.
Teneligliptin stabilizes GLP1R protein and increasing the cAMP-dependent antioxidant response (Sirt1 activation) and its downstream signaling lead to b-cell function (GSIS) and survival under high glucose conditions. Teneligliptin ameliorates high glucose-induced endoplasmic reticulum stress by reducing the ubiquitination of SERCA2b. Collectively, our results unveil a direct effect of Teneligliptin on beta-cell function and survival.
PO3-1
Activin A and Exendin-4 induce pancreatic ductal cell differentiation into b cell in vivo BACKGROUNDS: Activin A and/or exendin-4 have been shown to potentiate the differentiation of human pancreatic ductal cells into insulin-secreting cells in vitro and those cells, when implanted into the STZ-induced diabetic animals, could normalize their plasma glucose level. Here, we investigated an alternative method to differentiate pancreatic ductal cells into b cell in vivo by activin A and/or exendin-4. METHODS: Activin A and/or exendin-4 were injected intraperitoneally into STZinduced diabetic mice every other day for 30 days. Immunofluorescence-based beta-cell mass counting, glucose tolerance test, plasma insulin ELISA, and RT-PCR to check the markers of b-cell neogenesis and proliferation were performed. Undifferentiated human pancreatic ductal cells were also transplanted to the diabetic mice, and thereafter, activin A and/or exendin-4 were also administered in the same way. RESULTS: 30 days after activin A and exendin-4 administration, there were twofold increase in insulin-producing cells (beta-cell area), which were localized in proximity to pancreatic ducts. Fasting plasma glucose level decreased by 120-175% (P < 0.05), and there was a significant increase in plasma insulin concentration. Newly generated islets showed CK7 and insulin double-immunofluorescence staining, supporting that they are more likely to be derived from the ductal cells. In the transplantation experiments, insulin-producing cells with islet-like structures were detected in the graft and Ngn-3, PDX1 and NeuroD levels were increased compared to the nontransplanted control group. Plasma insulin level was 82% higher than the group without the transplantation. CONCLUSION: These results suggest that activin A and/or exendin-4 treatment could potentially stimulate the transdifferentiation of the pancreatic ductal cells into insulin-secreting b cell in vivo.
PO3-4
Cellular plasticity of islet cells in alloxan-treated diabetic mice Recent studies have demonstrated that pancreatic endocrine cells in the islets can transdifferentiate into insulin-producing cells under some stress conditions, and the reprogrammed insulin-producing cells are expected to lead to future cell therapies for the cure of diabetes. While polyhormonal (PH) cells that express both insulin and glucagon are observed in diabetic mouse models and have been shown to originate from a cells by lineage tracing studies, it remains to be elucidated what regulates the cellular plasticity under diabetic conditions. In the present study, we used a b-cell ablation model by injecting alloxan (ALX) into mice and found a time-dependent increase of PH cells after ALX injection. Although insulin treatment significantly improved blood glucose levels in ALX-treated mice, there was no significant difference in the number of PH cells compared with control mice.
Lineage tracing experiments, using Gcg-CreERTM; ROSA26-lacZ mice, demonstrated that more than 90% of PH cells originate from a cells (a-to-PH conversion), and lacZ-labeled insulin-positive/glucagon-negative cells, which shows a-to-b conversion, are also detected in ALX-treated mice.
On the other hand, there was no evidence of a-to-PH conversion in GcgCreERTM; ROSA26-lacZ; db/dbobese diabetic mice. These findings suggest that adult a cells in ALX-treated mice have a plasticity that allows them to be reprogrammed into polyhormonal cells or b cells.
Recent studies have demonstrated that pancreatic endocrine cells in the islets can transdifferentiate into insulin-producing cells under some stress conditions, and the reprogrammed insulin-producing cells are expected to lead to future cell therapies for the cure of diabetes. While polyhormonal (PH) cells that express both insulin and glucagon are observed in diabetic mouse models and have been shown to originate from a cells by lineage tracing studies, it remains to be elucidated what regulates the cellular plasticity under diabetic conditions. In the present study, we used a b-cell ablation model by injecting alloxan (ALX) into mice and found a time-dependent increase of PH cells after ALX injection. Although insulin treatment significantly improved blood glucose levels in ALX-treated mice, there was no significant difference in the number of PH cells compared with control mice.
PO4-6
The correlation between anti-GAD antibody titer evaluated by RIA and ELISA kit and pancreatic b-cell function Anti-glutamic acid decarboxylase (GAD) antibody is an autoantibody serving as an important marker in type 1 diabetes diagnosis. However, there have been serious problems in Japan regarding titers of GAD antibody measured using previously available radioimmunoassay (RIA) and newly available enzyme-linked immunosorbent assay (ELISA), especially among patients with weak positive in RIA (R-group; ≥1.5 U/mL and <10.0 U/mL). In this study, differences in titers of GAD antibody measured by the two assays among the R-patients were evaluated in regard with remaining b-cell function.
A total of 450 individuals with titers of GAD antibody evaluated by both RIA and ELISA were retrospectively analyzed. Among them, 66 R-patients with fasting plasma glucose (FPG) and C-peptide immunoreactivity (CPR) determined between one year before and after the day measuring titers of GAD antibody were analyzed studied for correlation between tires of GAD antibody and remaining b-cell function. Data were analyzed using t-test. Values are shown as mean -SD. In 44 patients positive by RIA measurement (R+; ≥10.0 U/mL), 34 cases were positive by ELISA measurement (E+; ≥5.0 U/mL) and 10 cases were negative (E-; <5.0 U/mL). In 66 R-patients, 23 cases were E+ and 43 cases were E-. In 340 patients negative by RIA measurement (R-; <1.5 U/mL), 9 cases were E+ and 331 cases E-. Among 66 patients R-, 38 patients were measured FPG and CPR over a year before and after the day of both RIA and ELISA measurements (measurement interval: 2.59 -2.03 years). At the point of RIA measurement, the C peptide index (CPI) was no significant difference between R-E+ and R-E-groups, but the time with ELISA measurement, the CPI was significantly lower in R-E+ (0.63 -0.72 vs. 1.22 -0.63). Furthermore, the proportion of patients with insulin-dependent (CPR <0.5 ng/mL) was significantly higher in R-E+ patients than in R-E-patients (59% vs. 4.8%) at ELISA measurement. This study suggests that beta-cell function in patients with R-E-did not show a
PO2-4
Protective effects of linagliptin on hepatic steatosis in mice treated with dual inhibitor for insulin receptor and IGF-1 receptor T. Okuyama, J. Shirakawa and Y. Terauchi Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama-City University, Yokohama, Japan Hepatic insulin signaling through its growth factor receptors is involved in the development of hepatic steatosis. We previously reported that systemic inhibition of insulin receptor (IR) and IGF-1 receptor (IGF-1R) by oral administration of OSI-906 (linsitinib), a dual IR/IGF1R tyrosine kinase inhibitor, for a week induced glucose intolerance, hepatic steatosis, and lipoatrophy in mice. We also reported that DPP4 inhibition prevented diet-induced adipose tissue inflammation and hepatic steatosis in diabetic mice. In this study, we investigated the effects of DPP-4 inhibition on hepatic steatosis in OSI-906-treated mice. Eightweek-old C57BL/6 mice were administrated 45 mg/kg of OSI-906 or vehicle with or without 3 mg/kg of linagliptin for 7 days. Linagliptin did not influence on hyperinsulinemia elicited by OSI-906. On the other hand, linagliptin reduced plasma triglyceride levels independent of blood glucose and serum insulin levels in OSI-906-treated mice. Linagliptin also improved OSI-906-induced hepatic steatosis without changes in visceral fat atrophy. Treatment with linagliptin partly reversed the increase in liver weight, hepatic triglyceride content, and glycogen content in OSI-906-treated mice. Hepatic gluconeogenic gene expressions, such as G6Pase, PEPCK and PGC-1a, were elevated by the administration of OSI-906, and linagliptin had no significant effect on those gene expressions. OSI-906-induced hepatic steatosis showed no significant changes in gene expressions of fatty acid synthesis or inflammation, such as SREBP-1c, TNF-a and IL-6. We also performed hepatic quantitative proteomic analysis in OSI-906-or linagliptin-treated mice. Among 1884 identified proteins, 232 proteins were significantly increased and 377 proteins were significantly decreased by the administration of OSI-906 compared with vehicle control. Linagliptin significantly upregulated 96 proteins and significantly downregulated 34 proteins in the liver of OSI-906-treated mice. We now focused on some candidate proteins for the amelioration of fatty liver by linagliptin in mice treated with OSI-906. Taken together, DPP4 inhibition with linagliptin improved hepatic steatosis induced by acute IR and IGF1R inhibition, suggesting an IR and IGF-1R signaling-independent pathway. Our findings support the potential action of DPP4 inhibitors for the treatment of hepatic steatosis under insulin-resistant conditions.
PO5-3
Myricetin protects against high glucose-induced b-cell apoptosis by attenuating endoplasmic reticulum stress via inactivation of cyclindependent kinase 5 Chronic hyperglycemia has deleterious effects on pancreatic b-cell function and turnover. Recent studies support the view that cyclin-dependent kinase 5 (CDK5) plays a role in b-cell failure under hyperglycemic conditions. However, little is known about how CDK5 impairs b-cell function.
Myricetin, a natural flavonoid, has therapeutic potential for the treatment of type 2 diabetes mellitus (T2DM). In this study, we examined the effect of myricetin on HG-induced b-cell apoptosis and explored the relationship between myricetin and CDK5.
To address this question, we subjected INS-1 cells and isolated rat islets to high glucose conditions (30 mM) in the presence or absence of myricetin. Docking studies were conducted to validate the interaction between myricetin and CDK5. Gene expression and Protein levels of ER stress markers were measured by real-time RT-PCR and western blot analysis.
Activation of CDK5 in response to high glucose coupled with the induction of endoplasmic reticulum stress via the downregulation of SERCA2b gene expression and reduced the nuclear accumulation of PDX-1 leads to b-cell apoptosis. Docking study predicts that myricetin inhibits CDK5 activation by direct binding in the ATP-binding pocket. Myricetin counteracted the decrease in the levels of PDX1 and SERCA2b by high glucose. Moreover, myricetin attenuated HG-induced apoptosis in INS-1 cells and rat islets and reduced the mitochondrial dysfunction by decreasing ROS production and mitochondrial membrane potential (Dwm) loss.
Myricetin protects the b cells against HG-induced apoptosis by inhibiting ER stress, possibly through inactivation of CDK5 and consequent upregulation of PDX1 and SERCA2b.
PP1-5
Effect of sodium-glucose co-transporter 2 inhibitor, empagliflozin, on hepatic steatosis in an animal model of type 2 diabetes 
